Mirador Capital Partners LP Purchases 956 Shares of Novartis AG (NYSE:NVS)
Mirador Capital Partners LP Purchases 956 Shares of Novartis AG (NYSE:NVS)
Mirador Capital Partners LP raised its holdings in shares of Novartis AG (NYSE:NVS – Get Rating) by 3.9% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 25,747 shares of the company's stock after acquiring an additional 956 shares during the quarter. Mirador Capital Partners LP's holdings in Novartis were worth $2,259,000 at the end of the most recent reporting period.
根据米拉多资本合伙公司提交给美国证券交易委员会的最新文件，该公司在第一季度将诺华制药(纽约证券交易所代码：NVS-GET评级)的股票持有量增加了3.9%。该机构投资者在本季度增持了956股后，持有该公司25,747股股票。在最近一个报告期结束时，Mirador Capital Partners LP持有的诺华公司股份价值225.9万美元。
A number of other hedge funds and other institutional investors also recently made changes to their positions in NVS. AHL Investment Management Inc. bought a new position in Novartis in the fourth quarter valued at $25,000. Dixon Hughes Goodman Wealth Advisors LLC bought a new position in shares of Novartis in the 4th quarter valued at about $32,000. Atwood & Palmer Inc. grew its holdings in shares of Novartis by 400.0% in the 1st quarter. Atwood & Palmer Inc. now owns 375 shares of the company's stock valued at $33,000 after acquiring an additional 300 shares in the last quarter. DeDora Capital Inc. acquired a new stake in shares of Novartis in the first quarter valued at about $34,000. Finally, Allegheny Financial Group LTD bought a new stake in Novartis during the fourth quarter worth about $34,000. 9.40% of the stock is currently owned by institutional investors and hedge funds.
其他一些对冲基金和其他机构投资者最近也调整了他们在NVS的头寸。AHL Investment Management Inc.在第四季度以25,000美元的价格购买了诺华的一个新头寸。Dixon Hughes Goodman Wealth Advisors LLC在第四季度购买了价值约3.2万美元的诺华新股头寸。今年第一季度，阿特伍德-帕尔默公司持有的诺华公司股票增加了400.0%。Atwood&Palmer Inc.现在持有375股该公司股票，价值33,000美元，上个季度又购入了300股。DeDora Capital Inc.在第一季度收购了价值约3.4万美元的诺华新股。最后，阿勒格尼金融集团有限公司在第四季度购买了诺华公司价值约3.4万美元的新股份。该公司9.40%的股票目前由机构投资者和对冲基金持有。
Analysts Set New Price Targets
分析师设定新的价格目标
NVS has been the subject of a number of analyst reports. Morgan Stanley raised their price target on Novartis from CHF 90 to CHF 94 in a research note on Friday, May 6th. Oppenheimer lowered shares of Novartis from an "outperform" rating to a "market perform" rating in a research report on Friday, June 3rd. JPMorgan Chase & Co. lifted their price objective on shares of Novartis from CHF 80 to CHF 81 and gave the company an "underweight" rating in a research report on Wednesday, July 20th. UBS Group upped their target price on shares of Novartis from CHF 85 to CHF 88 and gave the company a "neutral" rating in a report on Wednesday, April 27th. Finally, Wolfe Research cut Novartis from an "outperform" rating to a "market perform" rating in a research report on Monday, May 9th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Novartis has an average rating of "Hold" and a consensus target price of $87.33.
NVS一直是许多分析师报告的主题。摩根士丹利在5月6日星期五的一份研究报告中将诺华的目标价从90瑞士法郎上调至94瑞士法郎。在6月3日星期五的一份研究报告中，奥本海默将诺华公司的股票评级从“跑赢大盘”下调至“市场表现”。摩根大通公司在7月20日星期三的一份研究报告中将诺华公司的股票目标价从80瑞士法郎上调至81瑞士法郎，并给予该公司“减持”评级。瑞银集团在4月27日周三的一份报告中将诺华公司的股票目标价从85瑞士法郎上调至88瑞士法郎，并给予该公司“中性”评级。最后，沃尔夫研究公司在5月9日星期一的一份研究报告中将诺华公司的评级从“跑赢大盘”下调至“市场表现”。两名股票研究分析师对该股的评级为卖出，八名分析师给予持有评级，三名分析师给予买入评级，一名分析师对该公司股票给予强烈买入评级。根据MarketBeat的数据，诺华的平均评级为持有，共识目标价为87.33美元。
Novartis Stock Performance
诺华公司股票表现
Novartis (NYSE:NVS – Get Rating) last released its quarterly earnings results on Monday, July 18th. The company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.52 by $0.04. Novartis had a net margin of 44.31% and a return on equity of 21.88%. The business had revenue of $12.78 billion for the quarter, compared to the consensus estimate of $12.78 billion. During the same period in the prior year, the company posted $1.64 earnings per share. Novartis's revenue was down 1.4% compared to the same quarter last year. On average, equities analysts forecast that Novartis AG will post 6.06 EPS for the current year.
诺华公司(纽约证券交易所代码：NVS-GET Rating)最近一次发布季度收益报告是在7月18日星期一。该公司公布本季度每股收益为1.56美元，比普遍预期的1.52美元高出0.04美元。诺华的净利润率为44.31%，股本回报率为21.88%。该业务本季度营收为127.8亿美元，而市场普遍预期为127.8亿美元。去年同期，该公司公布的每股收益为1.64美元。与去年同期相比，诺华的营收下降了1.4%。股票分析师平均预测，诺华制药本年度每股收益将达到6.06股。
Novartis Profile
诺华简介
(Get Rating)
(获取评级)
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.
诺华制药在全球研究、开发、制造和营销保健品。该公司通过两个部门运营，创新药品和Sandoz。创新药品部门为患者和医疗保健提供者提供处方药。它还提供眼科、神经科学、免疫学、肝科、皮肤科、呼吸科、心血管、肾脏和新陈代谢药物产品。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Novartis (NVS)
- These Stocks Outperformed Last Time There Was A Recession
- Does Rivian's Stock Still Have A Future?
- Use These To Find Your Stock's Support and Resistance Levels
- Is Boeing Stock is Ready for Lift-Off ?
- Elon Musk is Out, But Should You Be In Twitter Stock?
- 免费获取StockNews.com关于诺华(Novartis)的研究报告
- 这些股票的表现优于上次衰退时的表现
- Rivian的股票还有前途吗？
- 用这些来找出你的股票的支撑位和阻力位
- 波音股票准备好起飞了吗？
- 埃隆·马斯克出局了，但你应该加入推特股票吗？
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.
接受诺华日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对诺华和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。